IBO — Impact BioMedical Inc.

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$7.7M

P/E Ratio

-1.64

Beta

6.38

52-Week Range

0.362-1.95

Dividend Yield

$0.00

CEO

Frank D. Heuszel

Employees

2

IPO Date

Sep 16, 2024

Exchange

AMEX